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specificity: 98.1%), the risk of failure is 9.8% (8/82) for patients 
not having received ADT. For patients who received ADT, the 
predictive factors of failure are PSA-60 (OR:53.9 p < 0.0001) and 
T-Stage (OR:0.25 p = 0.0008). Using this model and a PSA-60 cut-
off of 0.1 ng/mL (sensitivity: 85%, specificity: 92.9%), the 
predicted risk of BF in the rising PSA group is 53.7% (36/56). 
Taking into account the two predictive models, the anticipated 
cure rate for the entire cohort is 89.7%. 
Conclusions: Patients treated with LDR-PB monotherapy and 
whose PSA-60 is ≤ 0.3 ng/mL are highly likely to be cured even if 
they experienced a slight PSA rise. However, for patients who 
also received ADT, a stricter cut-off of 0.1 ng/mL may be 
appropriate. 
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Purpose:  The purpose of this study was to explore the cancer 
demographics in First Nations (FN) versus general population 
living in the remote island communities of Haida Gwaii, with 
similar access to cancer care services. 
Methods and Materials:  Medical charts of all 587 patients 
diagnosed with cancer from a period of 1970 until 2014 were 
retrieved from the British Columbia Cancer Agency registry and 
Northern Health database. Patients were categorized as FN or 
general population based on knowledge from community leader 
co-investigators. Estimates on breast cancer incidence in the 
period of 2001-2010 were calculated from the number of women 
in each community as per the Canadian Cancer Society census 
for that decade. Chi-square associations and multivariable Cox 
model was used to evaluate the association between FN versus 
non-FN status and mortality, after adjusting for clinical and 
treatment variables. 
Results:  A total of 587 patient charts were analyzed, with a 
median age at diagnosis of 62 years. Overall, 26% of cancer 
diagnoses were in patients of FN descent. Overall, 18% had 
confirmed smoking status, and 34% had a baseline performance 
status of 0-1. The most common cancer primary was genito-
urinary (GU: 17%), followed by gastro-intestinal (GI: 14%), breast 
(13%) and lung cancers (13%), while 14% were unknown. Stage I-
II presentation was seen in 21% and Stage III-IV was seen in 12% 
of the entire cohort. Surgery was performed in 26%, radiation 
therapy in 16% and chemotherapy was prescribed to 18%, but the 
status on cancer treatment was unknown in 54% of the cohort. 
The median number of trips made from the patient's hometown, 
up to and including initial treatment date was two (range, 1-5), 
with no difference between FN and non-FN group. Comparing FN 
versus non-FN population, significant clinical and treatment 
characteristics were: males (47% versus 58%; p = 0.03), breast 
cancer (23% versus 11%; p < 0.001), and GI cancers (22% versus 
13%; p < 0.001). There was no significant difference in overall 
survival (hazard ratio=1.28, 95% confidence interval: 0.77-2.16; 
p = 0.34).The estimated annual incidence for breast cancer in FN 
group was 2.2 cases per 1000, and 1.47 cases per 1000 for the 
non-FN population, while the Canadian estimate is 0.97 per 1000. 
Conclusions:  Breast cancer was more commonly seen in FN with 
an estimated 50% increased incidence of breast cancer as 
compared to the general population in Haida Gwaii, though the 
study sample size is small. The cancer care pathway and overall 
survival appear similar between the FN and non-FN cancer 
patients. 
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Purpose:  In the past decade, health care services for patients 
diagnosed with brain metastases have changed considerably with 
respect to decision-making, diagnostic sensitivity, systemic 
therapy options, surgical/radiosurgical approaches, and 
interdisciplinary management, including early palliative care 
support. Considering the combined effects of these changes, we 
hypothesized that, when compared to our institutional historical 
series of 2000-2005 (published 2011), survival has improved for 
those brain metastases patients seen between 2011-2015.  
Methods and Materials: From January 2011 to December 2015, 
patients with a new diagnosis of brain metastases referred to our 
regional cancer centre were triaged by a clinical nurse specialist, 
including after-hours referrals to the on-call radiation 
oncologists. Prophylactic cranial irradiation, hematological 
malignancies, non-Canadian, and cases without a consultation 
visit were excluded. Historical data from 2000-2005 was cleaned 
and updated; out-of-province cases lost to follow up were 
excluded. Survival time was measured from date of CT/MR 
diagnosis to date of death or censored at last contact. 
Proportional hazard regression model was pre-specified to test 
period effect (2011-15 versus 2000-05), adjusting for age and 
primary (lung, breast, melanoma, others). Prior to survival 
analysis, a clinically meaningful median survival gain was defined 
as one month or more for lung, breast and melanoma primaries. 
Results: From 2011-15, 688 cases were referred, of whom 675 
were included in this analysis (82% have died); from 2000-05, 555 
cases. Median age was 63 years and 61 years, respectively. The 
2011-15 cohort comprised of lung, breast, melanoma, and other 
cancers in 54%, 17%, 7.8% and 21% respectively; for 2000-05, 62%, 
13%, 4.5% and 21%. Median survival was 3.9 months for the 2011-
15 cohort (CL 3.4-4.2 months; 36% at 6 months) and 3.1 months 
for 2000-05 (CL 2.8-3.5 months; 30% at six months), Log rank p = 
0.0002 (lung 3.8 months versus 3.0 months; breast 3.8 months 
versus 4.0 months; melanoma 5.9 months versus 4.7 months). 
Adjusted for age, survival improvement was significant for lung 
(HR 0.78, CL 0.67-0.91), but not breast (HR 0.83, CL 0.61-1.1) 
nor melanoma (HR 0.76, CL 0.43-1.3). 
Conclusions: Even though the pre-defined magnitude of survival 
gain was not observed, the combined effects of advances in 
diagnosis, therapeutic strategies, and interdisciplinary 
collaboration on patients with brain metastases were associated 
with a modest improvement in survival outcome. While 
subgroups of patients might have benefited more from aggressive 
management, two out of three patients succumbed within six 
months of diagnosis. Palliative, supportive and transitional care 
services remain a clinical priority for the majority of brain 
metastases patients. 
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